Speaker Profile

Ph.D., President & CSO, Vitatex Inc.
Biography

Wen-Tien Chen, PhD, President & CSO of Vitatex Inc., Stony Brook, NY., leads his Vitatex team to develop the invasive circulating tumor cell (iCTC) technology for metastasis-focused drug development and personalized cancer diagnosis. Current focus is to produce iCTC™ flow cytometry assays for assessing therapeutic response of patients in clinical trials and iCTC-Tx® drug response blood tests for examining efficacy of developing drugs. Wen-Tien is the inventor of Cell Adhesion Matrix (CAM) functional cell enrichment technology and tumor invasion biomarkers. He has 30+ years of experience with NIH funded research on the mechanism of metastasis. His approaches toward CTC practice and drug development are based on the analysis of metastasis-initiating tumor cells but no other methods based on size, physical properties, antibody and/or microfluidics to isolate CTCs.

Presentation Title and Company Description

Liquid Biopsy Showcase: Invasive Circulating Tumor Cell (iCTC) Blood Tests
Vitatex Inc. develops invasive circulating tumor cell (iCTC) technology for personalized cancer diagnosis. Vitatex launches iCTC™ flow cytometry assays for assessing therapeutic response of patients in clinical trials and iCTC-Tx® drug response blood tests for examining efficacy of developing drugs.